HC Wainwright Issues Optimistic Outlook for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at HC Wainwright increased their Q1 2026 EPS estimates for Kyverna Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.62) per share for the quarter, up from their prior estimate of ($0.88). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.61) EPS.

Several other equities research analysts have also recently weighed in on KYTX. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wells Fargo & Company boosted their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a report on Monday, December 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Trading Up 1.1%

KYTX opened at $8.87 on Wednesday. Kyverna Therapeutics has a one year low of $1.78 and a one year high of $13.67. The company has a market cap of $388.51 million, a P/E ratio of -2.43 and a beta of 2.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.75 and a current ratio of 7.75. The business’s 50-day simple moving average is $8.21 and its 200-day simple moving average is $7.70.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.80).

Institutional Trading of Kyverna Therapeutics

A number of large investors have recently made changes to their positions in KYTX. Empowered Funds LLC purchased a new position in Kyverna Therapeutics during the 4th quarter worth approximately $169,000. Quadrature Capital Ltd purchased a new stake in Kyverna Therapeutics in the fourth quarter valued at approximately $539,000. Millennium Management LLC boosted its holdings in shares of Kyverna Therapeutics by 7.6% in the fourth quarter. Millennium Management LLC now owns 593,369 shares of the company’s stock valued at $5,578,000 after acquiring an additional 41,734 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $9,220,000. Finally, 683 Capital Management LLC purchased a new position in shares of Kyverna Therapeutics during the fourth quarter worth approximately $1,080,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.